Annovis Bio (ANVS) investor relations material

Executive summary

• Focused on late-stage clinical development of buntanetap for Alzheimer's and Parkinson's diseases, with multiple ongoing and completed clinical trials showing promising efficacy and safety results in targeted patient populations.

• Achieved full enrollment of 850 patients in pivotal Phase 3 Alzheimer's disease trial, surpassing the original target of 760; Parkinson's disease open-label extension study enrolled 266 patients, with full enrollment expected in Q4 2026.

• Topline data for Alzheimer's trial expected in Q1 2027, with regulatory preparations underway and additional open-label extension studies planned.

• Promoted Cheng Fang, Ph.D., to Chief Scientific Officer to oversee clinical and scientific progress.

• No revenue generated to date; operations funded primarily through equity and warrant issuances.

Financial highlights

• Net loss of $14.8 million for Q2 2026, up from $6.2 million in Q2 2025; net loss of $32.4 million for the six months ended June 30, 2026, compared to $11.8 million for the same period in 2025.

• Research and development expenses rose to $12.0 million in Q2 2026 (from $5.2 million in Q2 2025), driven by increased clinical trial activity.

• General and administrative expenses increased to $2.4 million in Q2 2026 (from $1.1 million in Q2 2025), mainly due to higher stock compensation and payroll.

• Cash and cash equivalents were $18.7 million as of June 30, 2026.

• Total operating expenses for Q2 2026 were $14.4 million.

Outlook and guidance

• Current cash is expected to fund operations until Q4 2026; substantial doubt exists about the ability to continue as a going concern without additional capital.

• Topline symptomatic data from the pivotal Alzheimer's trial expected in Q1 2027, with disease-modifying data a year later.

• Plans to raise further capital through equity, debt, or other alternatives; may defer certain expenses if needed.

• Anticipates continued elevated operating expenses as clinical programs progress.